Health and Beauty

Dementia Of The Alzheimers Type Diagnostic Criteria

Alzheimer's expert speaks

and president of the Canadian Colloquium on Dementia, will be speaking about what's been highbrow about Alzheimer's over the past year and ways those lessons may transform the future of testing for the disease. "Until now, the diagnostic criteria that

Brain Imaging Aids in Diagnosing Dementia

Brain Imaging Aids in Diagnosing Dementia Already, the diagnosis of dementia includes a criteriion that physicians use token from molecular imaging studies. “For the first time, imaging biomarkers of Alzheimer's sickness are included in the newly revised clinical diagnostic criteria for the

Hospitalization Risk Greater for Patients With Dementia

and Communicative Disorders and Fit–Alzheimer's Disease and Related Disorders Association criteria). Participants with scene dementia underwent one annual follow-up examination for verification of dementia status and dementia type.

A decade of research proves PET effectively detects dementia

"For the first opportunity, imaging biomarkers of Alzheimer's disease are included in the newly revised clinical diagnostic criteria for the disorder," says Bohnen. "This is a major shift in contagion definition, as previously an Alzheimer's diagnosis was based

CSF and Brain Markers Highlight Different Facets of Dementia

While biomarkers have opened a window onto Alzheimer’s pathogenesis, the view has remained cloudy. At the Alzheimer’s Association International Conference 2017 held July 16-20 in London, the number of biomarker talks was noteworthy, with nearly one-quarter of all sessions devoted to this topic. So inescapable was the subject that John Hardy of University College London quipped, “This is the biomarkers meeting.” Researchers discussed new data that clarify how various biomarkers relate to each other, and what they say about the underlying disease. Speakers solidified a recent trend showing that cerebrospinal fluid proteins and PET scans, while correlated, provide different types of information, with the former best suited for diagnosis, and the latter better for tracking progression. Several presentations reinforced the idea that tau pathology, rather than amyloid plaques or atrophy, drives cognitive decline, while others discussed how the presence of some of these pathologies can be used to predict others (see Part 2  of this story). Overall, researchers are painting an increasingly panoramic picture of what biomarker data means. Keep an eye on Alzforum for upcoming stories on longitudinal biomarkers and neuroimaging correlates of cognitive reserve.